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Background: The (mis)use of fluoroquinolones in the fowl industry has led to an alarming incidence of
fluoroquinolone resistance in pathogenic as well as commensal bacteria. Next to simply reducing antimicrobial
consumption, optimizing dosage regimens can be regarded as a suitable strategy to reduce antimicrobial resistance
development without jeopardizing therapy efficacy and outcome. A first step in order to limit antimicrobial
resistance is to assess the exposure of the intestinal microbiota to enrofloxacin after different treatment strategies.
Therefore, a study was conducted in broiler chickens to assess the effect of route of administration (oral versus
intramuscular) and dose escalation (10 and 50 mg/kg body weight) on plasma and intestinal concentrations of
enrofloxacin and its main metabolite ciprofloxacin after treatment with enrofloxacin once daily for five consecutive
days. Four different parts of the intestinal tract were sampled: ileum, cecum, colon and cloaca. A liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method was developed to quantify both analytes in
plasma and intestinal content. Sample preparation prior to LC-MS/MS analysis consisted of extraction with ethyl
acetate. For intestinal content samples PBS buffer was added before extraction. The supernatant was evaporated
to dryness and resuspended in water prior to analysis.
Results: The results in plasma and intestinal content demonstrated that biotransformation of enro- to ciprofloxacin
in broiler chickens is limited. In general, the intestinal microbiota in cecum and colon is exposed to significant
levels of enrofloxacin after conventional treatment (21–130 μg/g). A clear increase of intestinal concentrations was
demonstrated after administration of a five-fold higher dose (31–454 μg/g). After intramuscular administration,
intestinal concentrations were comparable, except for the higher levels in cloaca due to the complete bioavailability
and urinary excretion.
Conclusions: The intestinal microbiota is exposed to high levels of the antimicrobial, after oral as well as parenteral
therapy. Furthermore, a dose and time dependent correlation was observed. The impact of the detected intestinal
levels on resistance selection in the intestinal microbiota has to be further investigated.
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Enrofloxacin is a fluoroquinolone chemotherapeutic fre-
quently used in veterinary medicine. This broad spectrum
antimicrobial is indicated in poultry for the treatment of
respiratory and intestinal tract infections caused by Myco-
plasma gallisepticum, Mycoplasma synoviae, Avibacterium
gallinarum, Pasteurella multocida and Escherichia coli* Correspondence: mathias.devreese@ugent.be
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unless otherwise stated.(E. coli). The (mis)use of this class of drugs in the
fowl industry has led to an alarming incidence of
fluoroquinolone resistance in pathogenic as well as
commensal bacteria [1]. According to a recent report
by the European Food Safety Authority (EFSA), cipro-
floxacin resistance in Salmonella spp., Campylobacter
jejuni, Campylobacter coli and the indicator bacteria
E. coli derived from domestic fowl was 37.3%, 44.1%,
78.4% and 57.6%, respectively [2]. Ciprofloxacin is used as
representative for the fluoroquinolones as it is used in
human medicine and it is also the major metabolite ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sation of enro- to ciprofloxacin is limited, 5 to 10% [3,4].
The high rate of fluoroquinolone resistance is not only of
concern for veterinary medicine (e.g. treatment failure)
but also for human medicine as resistant bacteria can be
transferred through the food chain, through direct contact
with animals or through the environment (contaminated
soil) [5].
A clear association between antimicrobial drug use
and appearance of antimicrobial resistance has been
demonstrated [6,7]. These issues have led to an increasing
awareness to reduce the use of critically important antimi-
crobials in intensively reared livestock, for example by
prohibiting the use of antimicrobials as growth promoters
in Europe since 2006 [8], the ban to use fluoroquinolones
in the US since 2005 [9] and implementing control sys-
tems monitoring antimicrobial consumption in several
European countries including the Netherlands (MARAN),
Denmark (DANMAP) and Belgium (AMCRA).
Next to simply reducing antimicrobial consumption,
optimizing dosage regimens can be regarded as a suitable
strategy to reduce antimicrobial resistance development
without jeopardizing therapy efficacy and outcome. The
current posology of veterinary antimicrobial drugs is de-
termined by dose titration and confirmation studies solely
monitoring clinical efficacy. Limiting the emergence and
spread of resistance is not taken into account in these
studies. Haritova et al. (2011) [10] showed that a high dose
of enrofloxacin given in a short time resulted in better
eradication of pathogenic E. coli (O78/H12) in broiler
chickens compared to the conventional treatment. Further-
more, it has been suggested that parenteral administration
is preferred over oral administration as the intestinal
commensal microbiota is less exposed to the antimicrobial
leading to more limited resistance selection [11]. Never-
theless, the low economic value of individual birds makes
parenteral therapy cost ineffective and drinking water is
the preferred route to administer mass medication as sick
birds continue to drink. Furthermore, some considerations
have to be made with intramuscular administration to
birds. Necrotic lesions in the pectoral muscles can occur
after intramuscular injection in the breast muscle, hereby
reducing the quality of the resulting meat [12]. Injection in
the leg muscle on the other hand, might lower the bioavail-
ability of the drug through direct elimination in the kidneys
because of the renal-portal system [13]. Recently, the Sci-
entific Committee of the Federal Agency for the Safety of
the Food Chain (FASFC) of Belgium reported that the few
studies evaluating the effect of oral versus parenteral ther-
apy on resistance selection in the intestinal commensal
microbiota are inconclusive [14]. In order to optimize the
dosage strategy of fluoroquinolones in poultry, taking
resistance selection of the intestinal microbiota into
account, a first objective is to determine the antimicrobialexposure of the intestinal microbiota after different
treatments.
Therefore, the aim of the present study was to assess
and compare the plasma and intestinal concentration of
enro- and ciprofloxacin in broilers treated with the
conventional dosage regimen, broilers treated with an
elevated dose and the effect of oral versus parental route
of administration.
Methods
Chemicals, products and reagents
The analytical standards of enro-, cipro and sarafloxacin
(internal standard, IS) were obtained from Sigma-Aldrich
(Bornem, Belgium). Water, methanol and acetonitrile
(ACN) were of LC-MS grade and obtained from Biosolve
(Valkenswaard, The Netherlands). Glacial acetic acid and
ethyl acetate were of analytical grade and obtained from
VWR (Leuven, Belgium). Phosphate Buffered Saline (PBS)
was obtained from Life Technologies (Gent, Belgium).
Preparation of standard solutions
Separate standard stock solutions of enro-, cipro- and
sarafloxacin were prepared in 0.01 M acetic acid in
water (analyte concentration: 1 mg/mL) and were stored
at ≤ −15°C. A working solution of sarafloxacin and a com-
bined working solution of 0.1 mg/mL of enro- and cipro-
floxacin was prepared by transferring 100 μL of each stock
solution into an Eppendorf cup, followed by further dilu-
tion with water up to a final volume of 1.0 mL. Ten-fold
dilutions were obtained by dilution with water. All work-
ing solutions were stored at 2-8°C.
Animal experiment
Ninety-six three-week-old broiler chickens (Ross 308)
of mixed gender were equally divided in 4 groups and
allocated to a different treatment with enrofloxacin.
Animals had ad libitum access to feed and drinking
water throughout the experiment. After a one-week
acclimatization period, the animals of the first group
were administered the conventional treatment. Enrofloxa-
cin (Baytril® 10 % oral solution, Bayer, Diegem, Belgium)
was given as an oral bolus directly in the crop for 5 con-
secutive days (10 mg enrofloxacin/kg BW). The second
group received an elevated dose of enrofloxacin orally
(50 mg/kg BW) for five days. Enrofloxacin was given
intramuscularly (ad random as several separate injec-
tions in both breast muscles) for 5 days at a dose of 10
or 50 mg/kg BW (Baytril® 5%, Bayer) to the birds of the
other two groups.
From each group, eight animals were euthanized at each
sampling point, namely 2 and 4 h after the first adminis-
tration and 4 h after the last administration (100 h after
first administration). Euthanasia was performed by sodium
pentobarbital injection followed by exsanguination. Blood
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tent from ileum, cecum, colon and cloaca were collected.
Blood samples were centrifugated (2851 × g, 10 min, 4°C).
Aliquots (250 μL) of plasma samples were stored at ≤ −15°C
until analysis. Intestinal content samples of each treatment
group were pooled by segment and stored at ≤ −80°C until
analysis. This animal experiment was approved by the
Ethical Committee of Ghent University (Case number EC
2013_117).
Sample pretreatment
To 250 μL of plasma were added 12.5 μL of the IS work-
ing solution and vortex mixed (15 sec). Three mL of
ethyl acetate were added, samples were extracted for
15 min on a roller mixer (Stuart Scientific, Surrey, UK)
and centrifugated (2851 × g, 10 min, 4°C). Next, the
supernatant was transferred to another tube and evapo-
rated using a gentle nitrogen (N2) stream (45 ± 5°C). The
dry residue was reconstituted in 250 μL of water. After
vortex mixing (15 sec), the sample was transferred into
an autosampler vial and an aliquot (5 μL) was injected
onto the LC-MS/MS instrument.
To one gram of intestinal content, pooled per segment,
were added 100 μL of the IS working solution followed by
a vortex mixing step (15 sec) and addition of 3 mL PBS
and 5 mL ethyl acetate. Samples were then treated in the
same way as plasma samples. If the detected concentra-
tion was out of the linear range, samples were appropri-
ately diluted with PBS, re-extracted and re-analyzed.
Samples were analyzed in triplicate (technical replicates).
Liquid chromatography
The LC system consisted of a quaternary, low-pressure
mixing pump with vacuum degassing, type Surveyor
MSpump Plus and an autosampler with temperature con-
trolled tray and column oven, type Autosampler Plus, both
from ThermoFisher Scientific (Breda, The Netherlands).
Chromatographic separation was achieved on a Zorbax
Eclipse Plus column (100 mm × 3.0 mm i.d., dp: 3.5 μm) in
combination with a guard column of the same type
(13 mm × 3.0 mm i.d., dp: 3.5 μm), both from Agilent
(Diegem, Belgium). The temperatures of the column oven
and autosampler tray were set a 45°C and 5°C, respectively.
Mobile phase A consisted of 0.1% glacial acetic acid in
water whereas mobile phase B was ACN. Following gradi-
ent elution program was run: 0–3.5 min (92% A, 8% B),
3.5-4.0 min (linear gradient to 80% A), 4.0-8.0 min (80% A,
20% B), 8.0-8.5 min (linear gradient to 92% A), 8.5-
13.0 min (92% A, 8% B). Flow rate was set at 500 μL/min.
Mass spectrometry and method validation
The LC column effluent was interfaced to a TSQ®
Quantum Ultra triple quadrupole mass spectrometer,
equipped with a heated electrospray ionization (h-ESI)probe operating in the positive ionization mode (all from
ThermoFisher Scientific). Instrument parameters were
optimized by syringe infusion of working solutions of
1 μg/mL of each compound (flow rate 10 μL/min) in
combination with the mobile phases (50% A, 50% B).
The following general MS/MS parameters were used:
spray voltage: 3800 V, vaporizer temperature: 300°C,
sheath gas pressure: 33 au (arbitrary units), ion sweep
gas pressure: 2.0 au, auxilliary gas pressure: 15 au, capillary
temperature: 300°C, collision pressure: −1.5 mTorr and
quad MS/MS bias: 2.9. The resolution for Q1 and Q3
were set at 0.7 peak width at half-height.
Acquisition was performed in the selected reaction
monitoring (SRM) mode. For each compound, the two
most intense product ions of the precursor ion were mon-
itored in the SRM mode for quantification and identifica-
tion, respectively. The SRM transitions for enro-, cipro
and sarafloxacin were m/z 360.0 > 316.2*/245.1, 332.0 >
288.1*/314.1 and 386.1 > 299.0*/368.0, respectively. The *
indicates the ion used for quantification.
The method was validated for enro- and ciprofloxacin
in plasma as well as intestinal content according to a
validation protocol previously described by De Baere
et al. (2011) [15]. A set of parameters that were in com-
pliance with the recommendations and guidelines de-
fined by the European Community and with criteria
described in the literature, were evaluated [16-18].
Statistical analysis
After determination of normality and homogeneity of
variances, one-way ANOVA (SPSS 20.0, IBM, Chicago,
IL, USA) was performed on the results from the four
different treatments within each matrix and sampling
time point. A Scheffé test was performed as post-hoc test.
The significance level was set at 0.05.
Results
LC-MS/MS method
Matrix-matched calibration graphs (1/x2 weighed) were
linear over the working concentration range for enro-
and ciprofloxacin in both plasma and intestinal content
(see Additional file 1), with r values ranging between
0.9964 and 0.9988 and g values between 4.3% and 8.7%.
The within- and between run accuracy and precision
was evaluated at 2 or 3 concentration levels and fell
within the acceptability ranges (see Additional file 2).
The limits of quantification (LOQ) were 50 and 20 ng/
mL for enro- and ciprofloxacin in plasma, respectively,
whereas in intestinal content the LOQ was 100 ng/g.
The limits of detection (LOD) varied between 0.07 and
1.19 ng/mL or ng/g (see Additional file 1). Matrix effects
(signal suppression or enhancement, SSE) were deter-
mined and were 85.1% and 84.4% for enro- and cipro-
floxacin in plasma, respectively, and 85.9% and 73.2% for
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Moreover, this limited signal suppression was outweighed
by the IS displaying a similar retention time.
Animal experiment
The plasma concentrations of enro- and ciprofloxacin
after oral or intramuscular administration are presented
in Figure 1. Values present the mean (+ standard devi-
ation, SD) of the 8 birds/group. Biotransformation of
enro- to ciprofloxacin in broiler chickens is limited, as
can be concluded from the concentration ranges mea-
sured for enrofloxacin: 1.66 to 14.04 μg/mL compared to
ciprofloxacin: 0.08 to 0.65 μg/mL. The time of sampling,
namely 2 or 4 h after first administration or 4 h after last
administration (100 h), had a limited influence of the
plasma levels of enro- and ciprofloxacin. However, dose
escalation, from 10 mg/kg BW to 50 mg/kg BW, led to
linearly increased plasma concentrations. At a dose of
10 mg/kg, the administration route (oral, PO, versus
intramuscular, IM) altered the mean plasma concentra-
tions only at 100 h (PO: 2.64 ± 0.42 μg/mL, IM: 1.66 ±
0.17 μg/mL) but not at 2 (PO: 3.02 ± 0.77 μg/mL, IM:
4.41 ± 1.26 μg/mL) and 4 h (PO: 2.69 ± 0.38 μg/mL, IM:
2.66 ± 0.31 μg/mL). In contrast, at the elevated dosage of
50 mg/kg, plasma levels at 2 (PO: 9.27 ± 1.15 μg/mL,
IM: 14.04 ± 1.93 μg/mL) and 4 h (PO: 6.63 ± 1.12 μg/mL,
IM: 12.66 ± 3.53 μg/mL) post administration were higher
after parenteral administration, but not at 100 h (PO:
10.32 ± 1.62 μg/mL, IM: 8.54 ± 4.41 μg/mL).
Intestinal concentrations of enro- and ciprofloxacin
after treatment with enrofloxacin are presented in
Figures 2 and 3, respectively. The values are presented as
mean + SD of the three technical replicates from the
pooled samples. Similar to the plasma results, the in-
testinal concentrations reported here indicate limitedFigure 1 Plasma concentrations (average + SD) of enro- (A) and ciproflo
(IM) administration of 10 or 50 mg enrofloxacin/kg body weight to bro
the different treatment strategies with a different superscript within one
different at p < 0.05. The inserts show the chemical structure of enro- (biotransformation of enro- to ciprofloxacin. Furthermore,
a linear increase in enro- and ciprofloxacin levels after
enrofloxacin dose escalation was observed. The route of
administration had a limited effect on cecum and colon
concentrations, whereas ileal and cloacal levels were re-
spectively lower and higher after intramuscular adminis-
tration at both doses used.Discussion
LC-MS/MS method
This paper describes a validated LC-MS/MS method for
the quantification of enrofloxacin, and its main metabol-
ite ciprofloxacin in plasma and intestinal content of
broiler chickens. Several methods for detection of fluor-
oquinolones in biological fluids have been described in
literature. In the last decade, LC-MS/MS became the
method of choice due to its high sensitivity and selectiv-
ity. Sample preparation generally exists of protein pre-
cipitation, solid-phase extraction (SPE) or liquid-liquid
extraction. Protein precipitation is a cost effective and
rapid procedure, however, matrix components can be
enriched resulting in significant signal suppression or
enhancement (SSE) or loss of sensitivity. SPE on the
other hand, is generally time consuming and more ex-
pensive. A critical factor in the liquid-liquid extraction
of amphoteric compounds such as fluoroquinolones is
the neutralization of ionic compounds prior to extrac-
tion with e.g. ethyl acetate (pKa of carboxylic acid of
enro- and ciprofloxacin: 6.0; pKa of the piperazine ring
(amine functional group) of enro- and ciprofloxacin: 8.8
and 7.8 respectively) (Figure 1) [19]. To neutralize the
variable pH of intestinal content effect, PBS was added
prior to extraction. For plasma, a buffer was redundant
as the pH is constant at ± 7.4. As expected, extractionxacin (B) 2, 4 and 100 hours after the first oral (PO) or intramuscular
iler chickens given during 5 consecutive days (n = 8). Values from
time point, for the same compound ((A) or (B)), are statistically
A) and ciprofloxacin (B).
Figure 2 Enrofloxacin concentrations (average + SD of the three technical replicates) in different parts of the intestinal tract content:
ileum (A), cecum (B), colon (C) and cloaca (D), after oral (PO) or intramuscular (IM) administration of 10 mg enrofloxacin/kg BW or
50 mg enrofloxacin/kg BW a day for 5 consecutive days to broiler chickens. Pooled samples (n = 8) were taken at 2, 4 and 100 h after first
administration. Values from the different treatment strategies with a different superscript within one time point and within one intestinal
segment are statistically different at p < 0.05.
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est recoveries compared to acid or alkali conditions [20].
Chromatographic separation of fluoroquinolones is
commonly performed by a combination of an organic
solvent (ACN or methanol) and water with a volatile
acid (e.g. acetic acid or formic acid) [21]. The most opti-
mal chromatographic conditions were obtained with ACN
in combination with 0.1% acetic acid in water. Concerning
the MS/MS parameters, the highest sensitivity was ob-
tained for the protonated parent compounds measured in
the positive ESI mode and the followed SRM traces were
in accordance with literature [19,21,22].
Animal experiment
Current treatment strategies with antimicrobials exert a
selective pressure not only on the pathogen where the
treatment was intended for but also on the intestinal
microbiota. To optimize dosage strategies and evaluatedifferent administration routes, microbiota exposure data
are mandatory. Therefore, an animal experiment was per-
formed to assess and compare plasma and intestinal con-
centrations of enro- and ciprofloxacin after treatment of
broiler chickens with the conventional dosage regimen
(10 mg/kg BW), after a five-fold dose escalation and using
different administration routes (oral and intramuscular).
Unlike in other animal species, biotransformation of
enro- to ciprofloxacin is limited in poultry [3,23,24] and
adds only minimally to the antimicrobial effect of enro-
floxacin. At the Tmax (2 h) after oral dosing the conven-
tional treatment, mean maximum plasma concentration
(Cmax) of enrofloxacin was 3.0 μg/mL, which is compar-
able to other literature reports [25]. The mean Cmax of
4.4 μg/mL after 10 mg/kg BW intramuscular administra-
tion is also comparable to literature, where the Cmax after
5 mg/kg BW IM was 2.1 μg/mL [20]. Furthermore, the in-
crease of enro- and ciprofloxacin plasma concentrations
Figure 3 Ciprofloxacin concentrations (average + SD of the three technical replicates) in different parts of the intestinal tract content:
ileum (A), cecum (B), colon (C) and cloaca (D), after oral (PO) or intramuscular (IM) administration of 10 mg enrofloxacin/kg BW or
50 mg enrofloxacin/kg BW a day for 5 consecutive days to broiler chickens. Pooled samples (n = 8) were taken at 2, 4 and 100 h after first
administration. Values from the different treatment strategies with a different superscript within one time point and within one intestinal segment are
statistically different at p < 0.05.
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described in broiler chickens and pigs by [10] and [26],
respectively.
After oral bolus administration of enrofloxacin, a time
dependent shift in enrofloxacin concentration was ob-
served along the intestinal tract. Two hours after the
first administration, the highest levels were detected in
the ileum (10 mg/kg BW: 46.0 μg/g; 50 mg/kg BW:
214.9 μg/g), whereas four hours after first and last admi-
nistration, the highest concentration were detected in
the cecum (10 mg/kg BW: 112.1 μg/g after 4 h and
130.2 μg/g after 100 h; 50 mg/kg BW: 233.5 μg/g after
4 h and 453.6 μg/g after 100 h) and colon (10 mg/kg
BW: 51.6 μg/g after 4 h, 67.2 μg/g after 100 h; 50 mg/kg
BW: 254.9 μg/g after 4 h, 395.5 μg/g after 100 h). This
corresponds with the fast transit time in fed chickens
[27,28]. A similar time dependent shift of enrofloxacin
from small to large intestine was already described in pigs[29]. As for plasma levels, a dose dependent correlation
was observed for both oral and intramuscular adminis-
tration. This corresponds with the results of Wiuff et al.
(2003) [26] where an increase of the applied intramuscular
dose led to elevated fecal concentrations in pigs (14.6 to
160.0 μg/g after administration of 2.5 to 15.0 mg/kg BW).
In the present study, enro- and ciprofloxacin levels in the
colon are comparable between oral and intramuscular
administration: 30 – 67 and 44 – 86 μg enrofloxacin/g
after 10 mg/kg BW PO and IM, respectively, and 1.8 – 4.1
and 2.6 – 5.2 μg ciprofloxacin/g after 10 mg/kg BW PO
and IM, respectively. These high intestinal concentration
after intramuscular administration may be attributed to
biliary excretion and/or passive diffusion of fluoroquino-
lones based on their high volume of distribution (5.8 L/kg)
and the relatively limited plasma protein binding (< 20%)
[20,25,30]. Wiuff et al. (2002; 2003) [26,29] did not ob-
serve effects of administration route on fecal contents of
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after intramuscular administration (65 – 110 μg/g after
10 mg/kg BW) were higher compared to other intestinal
segments. This can be attributed to the complete bioavail-
ability after intramuscular administration compared to the
moderate to high oral bioavailability (64.0% to 89.2%)
[20,24,25] and to the fact that urine is the major route of
excretion for fluoroquinolones. Recent reports [4,31] de-
termined enrofloxacin concentration in poultry manure
during and after oral treatment with enrofloxacin. In the
study by Moraru et al. (2012) [31], broiler chickens were
treated with 10 mg enrofloxacin/kg BW for 5 days and
excreta samples were taken during and until 3 days post-
administration. Detected concentrations ranged between
40.5 to 50.7 μg/g. A similar study [4] reported enrofloxa-
cin concentrations in manure samples during treatment
(15 mg enrofloxacin/kg BW, orally) ranging between 39.2
and 55.0 μg/g. In our study, cloacal concentrations ranged
between 20.1 and 55.7 μg/g after oral treatment with
10 mg enrofloxacin/kg BW, which is comparable to the
other reports.
In general, intestinal enrofloxacin concentrations detec-
ted in the present study are much higher compared to
plasma concentrations. The ratio of enrofloxacin concen-
tration in intestinal content/plasma of the four different
treatment strategies ranges between 6.67 – 49.31, 6.59 –
43.96, 2.21 – 66.57 and 3.17 – 65.03 for treatment with
10 mg/kg BW PO, 50 mg/kg BW PO, 10 mg/kg BW IM
and 50 mg/kg BW IM, respectively (see Additional file 3).
The next step is to correlate the obtained data with ef-
fects on resistance selection in the intestinal microbiota.
This is done by correlating minimum inhibitory concen-
trations (MIC) with plasma pharmacokinetic characteris-
tics, called pharmacokinetic-pharmacodynamic or PK-PD
modelling. MIC values can be determined for pathogenic
as well as commensal bacteria. MIC values for wild-type
avian pathogenic E. coli (APEC) are variable and range
from 0.016 to 0.5 μg/mL [1,10]. The breakpoint of Cmax/
MIC ≥ 10 is an indicator for therapeutic efficacy of fluoro-
quinolones [32]. Hence, the conventional dosage regimen
would reach this breakpoint with a MIC of 0.016 μg/mL
(Cmax/MIC = 188) but not with a MIC of 0.5 μg/mL
(Cmax/MIC = 6). With an elevated dose (50 mg/kg BW),
the breakpoint value is reached even with the highest
MIC. Intestinal enrofloxacin concentrations were consid-
erably higher than plasma concentrations which would
lead to an eradication of the pathogenic E. coli in the in-
testine for all treatment strategies. However, resistant
commensal bacteria are more likely to transfer resistance
from animals to man (e.g. fecal carcass contamination).
For ciprofloxacin, the epidemiological cut-off value (ECOFF)
for resistance of commensal E. coli proposed by the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) is 0.03 μg/mL, but was recentlyadapted to 0.06 μg/mL [2]. Again, intestinal levels are
considerably higher than plasma levels and, based on
the ECOFF, this would imply a complete eradication of
susceptible bacteria.
The present study is the first to describe the enro- and
ciprofloxacin concentrations in different parts of the in-
testinal tract of broiler chickens after conventional and
alternative treatment strategies. To assess the possible
impact of enrofloxacin treatment on resistance selection
in the intestinal microbiota, concentration data in differ-
ent parts of the intestinal tract, and not only from fecal
droppings, is essential. Especially concentrations in cecal
and colonal content have to be measured as they harbor
the largest amount of intestinal bacteria.
To fully understand the impact of the reported en-
rofloxacin concentrations on the intestinal microbiota,
future research should apply these levels in an in vitro
gastro-intestinal simulation model or monitor the resist-
ance selection in vivo after different treatment strategies.
Furthermore, future research might also evaluate the
effect of continuous drinking water medication, which is
the preferred route of administration in poultry, on in-
testinal and plasma concentrations of enrofloxacin and
compare them with the results of single oral and paren-
tal administration presented in this study.
The authors would like to stress out that administra-
tion of a fivefold increased dose without reconsidering
the duration of the therapy, might lead to improper use
of fluoroquinolones. Also, the problem of drug residues
and withdrawal times should be considered in such case.
When assessing the effect of the different concentrations
reported in this study on resistance development or
selection, both dose and duration of therapy should be
considered. For instance, Haritova et al. (2011) [10]
demonstrated a better eradication of pathogenic E. coli
078/H12 in broiler chickens with a single oral adminis-
tration of 50 mg enrofloxacin/kg BW compared to oral
administration of 10 mg enrofloxacin/kg BW for 5 con-
secutive days.
Conclusions
This is the first paper describing enro- and ciprofloxacin
concentrations in content of different parts of the intes-
tinal tract, as well as in plasma, after different treatment
strategies of broiler chickens with enrofloxacin. In general,
the intestinal microbiota in cecum and colon is exposed
to significant levels of enrofloxacin after conventional
treatment (21–130 μg/g). A clear increase of intestinal
concentrations was demonstrated after administration of a
five-fold higher dose (31–454 μg/g). After intramuscular
administration, intestinal concentrations were compar-
able, except for the higher levels in cloaca due to the
complete bioavailability and urinary excretion. The impact
of the reported intestinal levels on resistance selection in
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e.g. using an in vitro gastro-intestinal simulation model
or monitor E. coli indicator bacteria in vivo after differ-
ent treatment strategies.
Additional files
Additional file 1: Results of the evaluation of linearity
(goodness-of-fit coefficient (g), correlation coefficient (r)), limit of
quantification (LOQ), limit of detection (LOD) for enrofloxacin
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